secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2025-06-04T23:59:59+00:00
Accession:  0000950170-25-081601
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan licenses BCMAxCD3 bispecific velinotamig from Genrix for $20M upfront, up to $692M milestones
--------------------------------------------------------------------------------

- Upfront license fee of $20 million; Genrix eligible for up to $292M in development/regulatory milestones and up to $400M in sales-based milestones.
- Tiered royalties on ex-Greater China net sales ranging from mid-single digit to mid-teens percent.
- Velinotamig has shown potential best-in-class efficacy in ~50 relapsed/refractory multiple myeloma patients; Cullinan to develop in autoimmune diseases.
- Genrix plans Phase 1 autoimmune study in China by end of 2025; Cullinan will conduct global development after that.
- Cullinan reiterates cash runway into 2028 based on current operating plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017025081601/0000950170-25-081601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017025081601/cgem-20250604.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-081601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer